China’s 15th Five-Year Plan for Pharma Spurs Stock Surge, AI Drug R&D Boosted
On September 18, ten Chinese government departments, led by the Ministry of Industry and Information Technology, issued the "15th Five-Year Plan for Pharmaceutical Industry Development," targeting over 3.5 trillion yuan in revenue and 20% annual growth for innovative drugs by 2030. The plan emphasizes AI, quantum computing, and supercomputing in drug R&D. On September 21, A-share and Hong Kong pharmaceutical stocks surged, with the CRO index rising over 5% and nearly 20 stocks hitting daily limits. The National Healthcare Security Administration also introduced a pre-pricing system for new medical technologies.
Reference imageEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- China has a massive biomedical data pool and a growing AI talent pool that give it real advantages in drug discovery.
- The dry-wet lab integration model, combining AI with contract research organizations, has genuine potential to speed up drug development.
- China's 15th Five-Year Plan shows strong government support for pharmaceutical innovation, including AI-driven drug discovery and clinical trial improvements.
- The global pharmaceutical landscape is becoming more multipolar, with China's NMPA gaining influence in emerging markets like ASEAN and Africa.
Points of contention
- Eastern Agent believes China's 30% share of global first-in-class drug candidates will lead to a similar share of approvals, while Neutral Agent argues most candidates fail and China's approval rate is historically worse.
- Eastern Agent compares China's pharma progress to its success in semiconductors, claiming state capital can brute-force biology, but Neutral Agent says drug discovery is probabilistic and can't be forced like chip manufacturing.
- Eastern Agent sees the 20% daily stock surges as institutional capital repositioning for a structural shift, while Neutral Agent dismisses them as retail speculation and hype-driven momentum.
- Neutral Agent insists FDA and EMA approval are essential for premium market revenue, while Eastern Agent argues China's NMPA and Belt and Road markets are becoming viable alternatives.
Blind spots
- Both agents overlook the challenge of data quality: China's massive patient records are fragmented across provinces and lack standardized coding, which could undermine AI-driven discoveries.
- Neither fully addresses how China's regulatory system, despite improvements, still lacks the rigorous clinical trial infrastructure and long-term follow-up data that the US and Europe have built over decades.
- The debate ignores the risk that geopolitical tensions could disrupt China's access to global scientific collaboration, talent flows, or critical research tools, slowing its pharma progress.
WorldAttention’s read
China's pharmaceutical sector has real structural advantages—a huge biomedical data pool, strong AI talent, and state-backed investment—that position it for long-term growth in drug discovery. However, the current market rally is driven more by hype than by proven results, as most drug candidates fail in clinical trials and China's approval rate for first-in-class drugs remains low. The key disagreement is about timing: Eastern Agent sees a rapid shift toward multipolar pharma leadership, while Neutral Agent warns that biology and regulatory hurdles will take years to overcome. Both sides agree the foundation is being built, but the leap from potential to approved drugs in premium markets is still a long, uncertain climb. Investors should focus on companies with validated pipelines and overseas revenue, not just narrative-driven stocks.
Reporting timeline
China's Pharma Stocks Surge on New Five-Year Plan; AI Drug Discovery Highlighted
Chinese pharmaceutical stocks rallied on September 23, driven by the release of the '15th Five-Year Plan for the Pharmaceutical Industry Development' by the Ministry of Industry and Information Technology and other departments. The plan aims to shift the industry from scale-driven to innovation- and quality-driven growth, targeting world-leading status by 2030. Citigroup analysts noted the plan broadly supports the entire value chain, including innovative drugs, AI-driven drug discovery, CRO/CDMO services, high-end medical devices, and innovative traditional Chinese medicine. The article also cites fund managers and analysts who view innovative drugs as the primary investment theme, with AI drug discovery gaining momentum. They highlight that the sector's structural opportunities require stock-picking, with a potential major rally expected in early 2025, contingent on data catalysts and business development deals. The report notes that AI computing power and wet-lab validation are emerging as key infrastructure for AI-driven pharmaceutical development.
China's 15th Five-Year Plan for Pharma Targets AI-Driven Drug Discovery and 20% Annual Innovation Growth
China's Ministry of Industry and Information Technology and nine other departments jointly released the '15th Five-Year Plan for Pharmaceutical Industry Development' on September 18, setting ambitious targets including an average annual growth rate of no less than 20% for innovative drug industry scale by 2030, first-in-class (FIC) drugs accounting for at least 25% of the global share, and R&D investment intensity of over 10% for listed pharmaceutical companies. The plan explicitly calls for 'deepening AI empowerment and upgrading' and 'accelerating AI-driven pharmaceutical R&D and production management paradigm shifts,' supporting AI and supercomputing in target discovery and molecular design. Separately, Novo Nordisk announced a partnership with Anthropic to use its AI models for drug discovery. The Shanghai STAR Biotech Index rose 1.94% on the news. Zhongtai Securities analysts believe the policy targets will concentrate resources on companies with original targets and international development capabilities, benefiting R&D outsourcing, clinical services, and high-end medical devices. The article also promotes the Kechuang Medical ETF (588130) as a diversified investment vehicle for the sector.
Read sourceChinese pharmaceutical stocks surge on new five-year plan and innovation policy support
On September 21, A-share pharmaceutical stocks surged, with the CRO index rising over 5% and the innovation drug index over 4%. Heyi Pharmaceutical hit a 30% daily limit. The rally was driven by the release of the '15th Five-Year Plan for Pharmaceutical Industry Development' jointly issued by ten Chinese government departments including the Ministry of Industry and Information Technology. The plan sets targets for the industry, including annual revenue exceeding 3.5 trillion yuan and innovation drug industry growth averaging over 20% annually. It emphasizes developing first-in-class (FIC) and best-in-class (BIC) drugs, accelerating AI and computing technologies in drug R&D, and supporting high-end medical devices. Additionally, the National Healthcare Security Administration introduced a pre-budgeting system for new medical technology pricing to speed up market access. Brokerages including Zhongtai Securities, Shenwan Hongyuan, and Huafu Securities issued positive outlooks, recommending innovation drug firms, AI-driven drug discovery platforms, and CXO companies as beneficiaries of the policy tailwinds.
Read sourceShow 13 older updatesHide older updates
China Pharma Stocks Surge on Policy Boost; CRO Index Jumps Over 5%
On Monday, A-share pharmaceutical stocks rallied sharply, with the CRO index surging over 5% and nearly 20 stocks hitting their daily limit or rising over 10%. The surge followed the release of the '15th Five-Year Plan' for the pharmaceutical industry by ten Chinese government departments, including the Ministry of Industry and Information Technology. The plan sets targets for the sector, including annual revenue exceeding 3.5 trillion yuan and an average annual growth rate of over 20% for innovative drug industry scale. It also encourages the development of first-in-class (FIC) and best-in-class (BIC) drugs and the application of AI, quantum computing, and computational medicine in drug R&D. Separately, the National Healthcare Security Administration announced a pre-pricing system for new medical technologies and products to accelerate their inclusion in medical service fee schedules. Analysts from Zhongtai Securities, Shenwan Hongyuan, and Huafu Securities expressed positive views on innovative drug chains, AI-driven drug discovery, and related upstream and downstream sectors, noting that the policies could benefit CXO companies, high-end medical device makers, and brain-computer interface firms.
Read sourceChinese Pharma Stocks Surge on Policy Boost; Analysts See AI Drug R&D Opportunities
On September 21, A-share pharmaceutical stocks surged, with the CRO index rising over 5% and nearly 20 stocks hitting their daily limit or gaining over 10%. The rally was triggered by the release of the '15th Five-Year Plan for Pharmaceutical Industry Development' by ten Chinese government departments, including the Ministry of Industry and Information Technology. The plan sets targets for the industry, including annual growth of over 20% for innovative drug scale and the creation of five or more blockbuster drugs with global sales exceeding $1 billion. It also encourages the use of AI, quantum computing, and other new technologies to empower drug R&D. Separately, the National Healthcare Security Administration introduced a pre-budgeting system for new medical technology pricing. Analysts from Zhongtai Securities, Shenwan Hongyuan, and Huafu Securities expressed positive views, highlighting opportunities for innovative drug companies, AI-driven drug discovery (AI4S), and the CXO supply chain. Huafu Securities noted that AI drug development is in an upward cycle, with increased capital and R&D budgets boosting upstream demand.
Read sourceChina's Pharma Stocks Surge on New Five-Year Plan Boosting AI Drug R&D and Innovation
Chinese A-share pharmaceutical stocks surged on September 21, with the CRO index rising over 5% and nearly 20 stocks hitting their daily limit, including a 30% surge for 峆一药业. The rally was triggered by multiple policy catalysts. On September 18, ten central government departments, including the Ministry of Industry and Information Technology, jointly issued the 'Fifteenth Five-Year Plan for the Development of the Pharmaceutical Industry,' which sets targets for the sector, including annual revenue exceeding 3.5 trillion yuan and an average annual growth rate of over 20% for the innovative drug industry. The plan emphasizes accelerating the use of artificial intelligence, quantum computing, and computational medicine to empower drug R&D, and supports the development of first-in-class (FIC) and best-in-class (BIC) drugs. Separately, the National Healthcare Security Administration announced a pre-budgeting system for new medical technology pricing to speed up market access. Analysts from 中泰证券, 申万宏源, and 华福证券 expressed bullish views on the innovative drug supply chain and AI-driven drug discovery (AI4S), noting that the policy will benefit CXO companies, AI platforms, and high-end medical device makers.
Read sourceUS-China Trade Breakthrough? Biotech Stocks Surge on Policy Hopes and AI Drug Advances
A-share and Hong Kong-listed innovative drug stocks surged on Monday, driven by a triple catalyst of improved overseas policy expectations, domestic industrial planning, and AI drug discovery breakthroughs. The most significant factor is a reported U.S. Treasury draft rule on biotech investment in China, which is expected to focus narrowly on pathogens and weaponizable technologies, potentially allowing U.S. pharma firms to invest in Chinese-developed new drugs. This would ease policy uncertainty for Chinese biotech firms' out-licensing deals. Domestically, China's 15th Five-Year Plan for the pharmaceutical industry targets over 3.5 trillion yuan in revenue by 2030 and 20% annual growth for innovative drugs. The National Healthcare Security Administration also introduced a new pricing system to speed clinical adoption. Additionally, Novo Nordisk's partnership with Anthropic and the industrial plan's support for AI-driven drug R&D boosted AI pharma stocks. However, analysts caution that the rally reflects policy expectation improvements, and investors must track final regulatory details and actual licensing orders to capture structural opportunities, as weak macro data and pre-holiday effects remain headwinds.
Read sourceAI Drug Discovery Stocks Surge on Anthropic Lab News and China's Five-Year Plan Support
On September 21, AI drug discovery (AIDD) stocks rallied in Chinese markets, with Nuohé Zhiyuan hitting its daily price limit within three minutes of opening. The surge followed dual catalysts: reports that AI firm Anthropic is building a wet laboratory in San Francisco to integrate computational and experimental biology, and China's release of the 15th Five-Year Plan for the pharmaceutical industry, which explicitly supports AI-powered drug development. Anthropic recently partnered with Novo Nordisk and acquired AI drug startup Coefficient Bio for $400 million. Domestically, ByteDance's spin-off AI drug company Xinsheng Tantu completed its first financing round at a $1.5 billion valuation. Brokerages including Dongwu Securities, Zhongtai Securities, Shanghai Securities, and Zheshang Securities issued positive outlooks, stating AI drug discovery is entering a value-validation phase with dry-wet lab integration as the core logic. Eight A-share concept stocks are forecast to double their net profits this year, according to consensus estimates from at least three brokerages. The article lists specific companies and their performance metrics, including Baiao Saitu, Baipu Saisi, and Diao'an Diagnostics.
Read sourceAI Drug Discovery Stocks Surge on Anthropic Lab Plans and China's 15th Five-Year Plan Support
On September 21, AI drug discovery (AIDD) concept stocks surged in China's A-share market, led by Novogene's 20% daily limit within three minutes of opening. The rally was driven by dual catalysts: overseas, AI firm Anthropic is reportedly building a wet laboratory in San Francisco to create a dry-wet experiment loop for AI-driven drug discovery, following its partnership with Novo Nordisk and acquisition of Coefficient Bio. Domestically, China's Ministry of Industry and Information Technology and nine other departments jointly issued the '15th Five-Year Plan' for pharmaceutical industry development, explicitly supporting AI-powered drug development as one of 25 key tasks. Brokerages including Dongwu Securities, Zhongtai Securities, Shanghai Securities, and Zheshang Securities published bullish notes, arguing that AI drug discovery is entering a value-validation phase with dry-wet closed loops becoming core. According to Oriental Fortune, 80 A-share stocks are involved in the AI drug discovery concept, with a combined market cap of about 1.25 trillion yuan. Analysts forecast that eight concept stocks, including Dian Diagnostics, Changchun High-Tech, and Zelgen Biopharma, could see net profit more than double this year, based on consensus estimates from at least three institutions.
AI Drug Discovery Stocks Surge in China on Novo Nordisk Deal and Government Plan
Shares of AI-powered drug discovery companies in China's A-share market rallied sharply on [date of article]. Novogene led the gains with a 20% daily limit rise, while Huiyu Pharmaceutical-W surged over 10%, and several other firms including Hongbo Medical, Yingsheng Life, and Pharmaron posted gains of 5-8%. The rally was attributed to two key catalysts. First, Danish pharmaceutical giant Novo Nordisk announced a partnership with AI company Anthropic to use its AI models, including Claude Science, for drug discovery and development. Second, China's Ministry of Industry and Information Technology, along with nine other government departments, jointly released the '15th Five-Year Plan for the Pharmaceutical Industry Development,' which explicitly calls for 'deepening AI empowerment and upgrading' and 'accelerating the AI-driven paradigm shift in pharmaceutical R&D and production management.' The plan also supports the application of frontier technologies such as AI and supercomputing in target discovery and molecular design.
Read sourceAI Drug Discovery and CRO Concepts Rally; Novogene Hits 20% Daily Limit Up
On September 21, AI drug discovery and CRO (Contract Research Organization) concepts continued their strong performance in the Chinese stock market, with Novogene hitting its 20% daily limit up. Other companies including Hongbo Pharmaceutical, Chengdu Lead Sci-Tech, Boji Pharmaceutical, Berry Genomics, and Seli Medical also followed with gains. The rally was driven by a policy announcement on September 18, when China's Ministry of Industry and Information Technology (MIIT) and nine other departments jointly issued the '15th Five-Year Plan for the Development of the Pharmaceutical Industry.' The plan proposes accelerating the empowerment of drug research and development through new technologies such as artificial intelligence, quantum computing, supercomputing, and computational medicine. It also explores new models for pharmaceutical and medical device production, including ultra-limited manufacturing, space-based drug production, and biomanufacturing. The report is attributed to CLS, a Chinese financial news outlet.
Read sourceChina's 15th Five-Year Plan Boosts Innovative Drugs; AI Drug Discovery Deals Surge
On September 21, Hong Kong stock markets rallied, with the CSI Hong Kong Innovative Drug Index rising over 5%. This followed the joint release of the '15th Five-Year Plan for the Pharmaceutical Industry' by ten Chinese government departments, including the Ministry of Industry and Information Technology. The plan calls for accelerating the use of AI, quantum computing, and supercomputing in drug R&D. Separately, the National Medical Products Administration pledged continued support for innovative drug and device development. The article also highlights multiple AI drug discovery collaborations: Novo Nordisk's partnership with Anthropic to test Claude Science, a collaboration between GenScript/Twist and Eli Lilly's AI platform Lilly TuneLab, and a $290 million Series A funding round for ByteDance-incubated AI drug platform Anew Labs. Analysts at Changcheng Guorui Securities recommend focusing on innovative drug companies with differentiated clinical value and global commercialization potential. The article notes that the Hong Kong Innovative Drug Index's PE-TTM is approximately 34 times, near a five-year historical low, and that a profit inflection point for biotech firms may have been reached in the first half of the year.
Read sourceAI Drug Discovery Stocks Surge on Novo Nordisk-Anthropic Deal and China Policy Support
On September 21, Chinese AI drug discovery (AI制药) stocks rallied sharply, driven by international and domestic catalysts. Internationally, Danish pharmaceutical giant Novo Nordisk announced a deep partnership with AI firm Anthropic to use its Claude Science platform for drug discovery, following Anthropic's $400 million acquisition of AI drug startup Coefficient Bio in April. Domestically, ByteDance's spun-off AI drug firm Xinshengtantu completed its first financing round at a $1.5 billion post-investment valuation. Chinese AI drug firms Insilico Medicine and XtalPi reported strong revenue growth. Policy support came from China's Ministry of Industry and Information Technology and nine other departments issuing the '15th Five-Year Plan' for pharmaceutical industry development, which emphasizes deepening AI applications. Analysts at China Securities and Shanghai Securities view AI drug discovery as entering a value validation phase, with potential for a 'Claude moment' in the pharmaceutical industry. The article identifies eight concept stocks expected to see net profit more than double this year, including Dian Diagnostics, Changchun High-Tech, and Zelgen Biopharmaceuticals.
Read sourceChinese pharmaceutical stocks surge on 15th Five-Year Plan and positive policy signals
Chinese pharmaceutical stocks surged on September 21, with the CRO index rising over 5% and nearly 20 stocks hitting their daily limit, including a 30% surge for Heyi Pharmaceutical. The rally was triggered by multiple policy catalysts. On September 18, ten Chinese government departments including the Ministry of Industry and Information Technology jointly issued the '15th Five-Year Plan for Pharmaceutical Industry Development,' setting targets for the sector including revenue exceeding 3.5 trillion yuan and annual growth of over 20% for innovative drugs. The plan emphasizes developing first-in-class and best-in-class drugs, accelerating AI and quantum computing applications in drug R&D, and supporting high-end medical devices. Additionally, the National Healthcare Security Administration issued a notice on September 15 establishing a pre-pricing system for new medical technologies to speed up their inclusion in medical service fee schedules. Analysts from Zhongtai Securities and Shenwan Hongyuan expressed positive views on innovative drug companies and the CXO supply chain, while Huafu Securities highlighted AI-driven drug discovery as a key downstream application for large models.
Read sourceChina's Pharma Stocks Surge on New Five-Year Plan, AI Drug Development Boost
Chinese pharmaceutical stocks surged on September 21, driven by multiple policy catalysts. The Ministry of Industry and Information Technology and nine other departments jointly issued the '15th Five-Year Plan for Pharmaceutical Industry Development,' setting targets including annual revenue exceeding 3.5 trillion yuan for large-scale pharmaceutical firms and an average annual growth rate of over 20% for innovative drug industry scale. The plan emphasizes AI empowerment, aiming to advance AI for Science (AI4S) from single-point tools to integrated data, model, and wet-lab collaboration. Separately, the National Healthcare Security Administration introduced a pre-project pricing system for high-tech medical services to accelerate reimbursement. Brokerages offered positive outlooks: Zhongtai Securities recommended globally competitive innovative drug firms, AI4S platforms, and integrated CXO companies; Shenwan Hongyuan highlighted innovative drug and supply chain stocks ahead of Q3 earnings; Huafu Securities noted AI drug development is entering an upcycle driven by both external capital and internal R&D budgets, benefiting upstream supply chains.
Read sourceCRO Concept Stocks Surge on China's 15th Five-Year Plan for Pharmaceutical Industry
On September 18, China's CRO (Contract Research Organization) concept sector saw a sharp rally, with Heyi Pharmaceutical hitting a 30cm daily limit-up. Other stocks including Jinan Protein, Chengdu Xian Dao, and Hongbo Pharmaceutical rose over 10%. The surge followed the release of the '15th Five-Year Plan for the Pharmaceutical Industry Development' by ten government departments including the Ministry of Industry and Information Technology. The plan calls for accelerating the application of new technologies such as artificial intelligence, quantum computing, supercomputing, and computational medicine in drug research and development. It also explores new production models for pharmaceuticals and medical devices, including ultra-limit manufacturing, space pharmaceuticals, and biomanufacturing. The policy aims to boost innovation and modernization in China's pharmaceutical sector.
Read source